专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018100558A8 CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS 审中-公开
公开(公告)号：WO2018100558A8
公开(公告)日：2018-06-07
申请号：PCT/IB2017/057588
申请日：2017-12-01
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： YOSHIKAWA, Masato , SAITOH, Morihisa , KATO, Taisuke , YOSHITOMI, Yayoi , SEKI, Tomohiro , NAKAGAWA, Yasuo , TOMINARI, Yusuke , SETO, Masaki , SASAKI, Yusuke , OKANIWA, Masanori , ODA, Tsuneo , SHIBUYA, Akito , HIDAKA, Kosuke , SHIOKAWA, Zenyu , MURATA, Shumpei , OKABE, Atsutoshi , NAKADA, Yoshihisa , MOCHIZUKI, Michiyo , FREEZE, Brian Scott , TAWARAISHI, Taisuke , WADA, Yasufumi , GREENSPAN, Paul D.
IPC分类号： C07H21/00 , C07H21/02 , A61K31/7084 , A61P35/00
摘要： The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

2. 发明申请

WO2018194181A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS 审中-公开
公开(公告)号：WO2018194181A1
公开(公告)日：2018-10-25
申请号：PCT/JP2018/016382
申请日：2018-04-17
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： SAKAI, Shinobu , SETO, Masaki , TAKAMI, Kazuaki , ANDO, Haruhi
IPC分类号： C07D405/14 , C07D405/04 , C07D409/14 , A61K31/495 , A61K31/517 , A61K31/5377 , A61P1/00
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I) : wherein each symbol is as described in the specification, salt thereof.

3. 发明申请

WO2018100558A9 CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTEFERON GENES) AGONISTS 审中-公开
公开(公告)号：WO2018100558A9
公开(公告)日：2018-06-07
申请号：PCT/IB2017/057588
申请日：2017-12-01
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： YOSHIKAWA, Masato , SAITOH, Morihisa , KATO, Taisuke , YOSHITOMI, Yayoi , SEKI, Tomohiro , NAKAGAWA, Yasuo , TOMINARI, Yusuke , SETO, Masaki , SASAKI, Yusuke , OKANIWA, Masanori , ODA, Tsuneo , SHIBUYA, Akito , HIDAKA, Kosuke , SHIOKAWA, Zenyu , MURATA, Shumpei , OKABE, Atsutoshi , NAKADA, Yoshihisa , MOCHIZUKI, Michiyo , FREEZE, Brian Scott , TAWARAISHI, Taisuke , WADA, Yasufumi , GREENSPAN, Paul D.
IPC分类号： C07H21/00 , C07H21/02 , A61K31/7084 , A61P35/00
摘要： The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

4. 发明申请

WO2018100558A3 CYCLIC PURINE DINUCLEOTIDES AS STING (STIMULATOR OF INTEFERON GENES) AGONISTS 审中-公开
公开(公告)号：WO2018100558A3
公开(公告)日：2018-06-07
申请号：PCT/IB2017/057588
申请日：2017-12-01
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： YOSHIKAWA, Masato , SAITOH, Morihisa , KATO, Taisuke , YOSHITOMI, Yayoi , SEKI, Tomohiro , NAKAGAWA, Yasuo , TOMINARI, Yusuke , SETO, Masaki , SASAKI, Yusuke , OKANIWA, Masanori , ODA, Tsuneo , SHIBUYA, Akito , HIDAKA, Kosuke , SHIOKAWA, Zenyu , MURATA, Shumpei , OKABE, Atsutoshi , NAKADA, Yoshihisa , MOCHIZUKI, Michiyo , FREEZE, Brian Scott , TAWARAISHI, Taisuke , WADA, Yasufumi , GREENSPAN, Paul D.
IPC分类号： C07H21/00 , C07H21/02 , A61K31/7084 , A61P35/00
摘要： The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

5. 发明申请

WO2018194181A8 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS 审中-公开
公开(公告)号：WO2018194181A8
公开(公告)日：2018-10-25
申请号：PCT/JP2018/016382
申请日：2018-04-17
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： SASAKI, Shinobu , SETO, Masaki , TAKAMI, Kazuaki , ANDO, Haruhi
IPC分类号： C07D405/14 , C07D405/04 , C07D409/14 , A61K31/495 , A61K31/517 , A61K31/5377 , A61P1/00
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I) : wherein each symbol is as described in the specification, salt thereof.

6. 发明申请

WO2019189945A1 HETEROCYCLIC COMPOUND AND USE THEREOF 审中-公开
公开(公告)号：WO2019189945A1
公开(公告)日：2019-10-03
申请号：PCT/JP2019/014901
申请日：2019-03-27
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： OGURO, Yuya , MATSUMOTO, Shigemitsu , WAKABAYASHI, Takeshi , TOKUNAGA, Norihito , KAMEI, Taku , ITO, Mitsuhiro , MIKAMI, Satoshi , SETO, Masaki , MORIMOTO, Shinji , NAKAMURA, Shinji , TAKASHIMA, Sachie , MURAKAMI, Masataka , DAINI, Masaki , KAMATA, Makoto , NAKAMURA, Minoru , WADA, Yasufumi , KAKEI, Hiroyuki , TAKAMI, Kazuaki , TAWARAISHI, Taisuke , AIDA, Jumpei , HIWANAGA, Kouichi , YAMAMOTO, Satoshi
IPC分类号： C07D471/04 , C07D487/04 , A61P25/00 , A61K31/437 , A61K31/4162
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

7. 发明申请

WO2018100558A2 CYCLIC DINUCLEOTIDE 审中-公开
公开(公告)号：WO2018100558A2
公开(公告)日：2018-06-07
申请号：PCT/IB2017/057588
申请日：2017-12-01
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： YOSHIKAWA, Masato , SAITOH, Morihisa , KATO, Taisuke , YOSHITOMI, Yayoi , SEKI, Tomohiro , NAKAGAWA, Yasuo , TOMINARI, Yusuke , SETO, Masaki , SASAKI, Yusuke , OKANIWA, Masanori , ODA, Tsuneo , SHIBUYA, Akito , HIDAKA, Kosuke , SHIOKAWA, Zenyu , MURATA, Shumpei , OKABE, Atsutoshi , NAKADA, Yoshihisa , MOCHIZUKI, Michiyo , FREEZE, Brian Scott , TAWARAISHI, Taisuke , WADA, Yasufumi , GREENSPAN, Paul D.
IPC分类号： C07H21/00 , C07H21/02 , A61K31/7084 , A61P35/00
CPC分类号： C07H21/02 , A61P35/00 , C07H21/00
摘要： The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I), wherein each symbol is as defined in the description, or a salt thereof.

8. 发明申请

WO2007097470A2 FUSED HETEROCYCLIC COMPOUND 审中-公开
标题翻译：熔融杂环化合物
公开(公告)号：WO2007097470A2
公开(公告)日：2007-08-30
申请号：PCT/JP2007/053859
申请日：2007-02-22
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , SETO, Masaki , OHASHI, Tomohiro
发明人： SETO, Masaki , OHASHI, Tomohiro
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： A compound of the formula: wherein ring' A is a 7-membered or 8-membered nitrogen- containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X 1 is a group represented by -NR 3 -Y 1 -, -0-, -S-, -SO-, -SO 2 - or -CHR 3 - wherein R 3 is a hydrogen atom or' an optionally substituted aliphatic hydrocarbon group, or R 3 may be bonded to the carbon atom of ring B to form an optionally substituted ring structure, and Y 1 is a bond or an optionally substituted C 1-4 alkylene, R 1 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, the formula = shows a single bond or a double bond, when ===R 2 is - R 2 , R 2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and when ===R 2 is =R 2 , R 2 is an oxo group, an optionally substituted alkylidene group, or an optionally, substituted imino group.
摘要翻译：下式的化合物：其中环A是任选进一步取代的7元或8元含氮环，环B是任选取代的芳基或任选取代的杂芳基，X 1 >是由-NR 3 -O - ， - O - ， - S - ， - SO - ， - SO 2 - - 或-CHR 3 - 其中R 3是氢原子或'任选取代的脂族烃基或R 3'可以键合到环B的碳原子形成任选取代的环结构，Y 1是一个键或任选取代的C 1-4亚烷基，R 1， / SUP>是氢原子或通过碳原子或硫原子键合的任选取代的基团，当= = R 2 - 时，式=表示单键或双键， R 2，R 2是氢原子或经由碳原子，氮原子，氧原子或硫原子键合的任选取代的基团，w 母鸡=== R 2是= R 2，R 2是氧代基，任选取代的亚烷基或任选取代的亚氨基组。

9. 发明申请

WO2007064045A1 FUSED HETEROCYCLIC COMPOUND 审中-公开
标题翻译：熔融杂环化合物
公开(公告)号：WO2007064045A1
公开(公告)日：2007-06-07
申请号：PCT/JP2006/324499
申请日：2006-12-01
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , ISHIKAWA, Tomoyasu , MIWA, Kazuhiro , SETO, Masaki , BANNO, Hiroshi , KAWAKITA, Youichi
发明人： ISHIKAWA, Tomoyasu , MIWA, Kazuhiro , SETO, Masaki , BANNO, Hiroshi , KAWAKITA, Youichi
IPC分类号： C07D487/04 , A61K31/519
CPC分类号： C07D487/04
摘要： The present invention provides a compound represented by the formula: wherein R 1a is a hydrogen atom, R 2a is a C 1-6 alkyl group substituted by a group represented by-NR 6a -CO-(CH 2 ) n -SO 2 -optionally halogenated C 1-4 alkyl wherein n is an integer of 1 to 4, R 6a is a hydrogen atom or a C 1-4 alkyl group, and -(CH 2 ) n - is optionally substituted by C 1-4 alkyl, R 3a is a hydrogen atom or a C 1-6 alkyl group, R 4a is a halogen atom or a C 1-6 alkyl group, R 5a is a halogen atom or a C 1-6 alkyl group, and X a is a hydrogen atom or a halogen atom, or a salt thereof. The compound of the present invention has a superior tyrosine kinase inhibitory action, is highly safe, and is sufficiently satisfactory as a pharmaceutical product.
摘要翻译：本发明提供由下式表示的化合物：其中R 1a是氢原子，R 2a是C 1-6烷基被-NR 6 - （CH 2）n - -SO 2 - 表示的基团取代。卤代C 1-4烷基，其中n为1至4的整数，R 6a为氢原子或C 1-4烷基基团和 - （CH 2）n - ）任选被C 1-4烷基取代，R 3a，是氢原子或C 1-6烷基，R 4a是卤素原子或C 1-6烷基，R 5a是卤素原子或C 1-6烷基，X a是氢原子或卤素原子，或盐它们。本发明的化合物具有优异的酪氨酸激酶抑制作用，是高度安全的，并且作为药物产品足够令人满意。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式